- Trial phase
- Phase 2
- Time to market
- If Phase 2 data in H2 2027 is positive, a Phase 3 program would follow, meaning potential FDA approval/commercialization is likely several years away, likely 2029-2031 at the earliest.
- Why 6/10
- The next hard, dated catalyst is the Phase 2 RELEASE study topline readout, expected in H2 2027 (approximately 8-13 months from now). This is a mid-stage readout, not a registrational/approval decision, and Protalix has other revenue-generating approved products (Elfabrio, Elelyso), so PRX-115 is a major pipeline driver but not the company's sole value. ImpactScore of 6 reflects a binary Phase 2 readout within ~6-12 months on a significant pipeline asset at a company with other programs.
The next major catalyst is the Phase 2 RELEASE study (NCT07280156) topline results, expected in the second half of 2027. Positive data showing sustained uric acid reduction with infrequent dosing could significantly de-risk the program and support a path to registration. Negative or equivocal results would likely weigh heavily on the stock given PRX-115's importance as the lead pipeline asset. Interim data or updates at medical conferences in the interim could also move the stock.
Price Chart
Executive Summary
PRX-115 is Protalix BioTherapeutics' (NYSE American: PLX) lead pipeline candidate, a recombinant PEGylated uricase for uncontrolled gout, designed to break down uric acid with less frequent dosing than the only approved competitor, Krystexxa (pegloticase). Phase 1 data presented at ACR 2026 showed a single 36 mg dose kept uric acid below target for up to 12 weeks, with drug levels measurable for up to 85 days. The Phase 2 RELEASE study (NCT07280156) is enrolling, with topline results expected in H2 2027. Protalix is already profitable with growing revenue from approved Fabry (Elfabrio) and Gaucher (Elelyso) products, providing a financial cushion. The stock trades at $2.86 with a mean analyst price target of $11, reflecting optimism about PRX-115's potential, though the long wait for Phase 2 data and competition from established Krystexxa are key risks.
How It Works
PRX-115 is a recombinant PEGylated uricase, an enzyme that breaks down uric acid in the blood. In uncontrolled gout, patients have persistently high uric acid levels that standard oral medications cannot control, leading to painful crystal deposits in joints. PRX-115 is designed to be injected intravenously, where it converts uric acid into a harmless substance called allantoin that the body can easily excrete. The drug is 'PEGylated' (coated with polyethylene glycol) to help it stay in the bloodstream longer and reduce the chance of immune reactions. It is produced using Protalix's proprietary ProCellEx plant cell-based platform.
Trial Status
Phase 1 single ascending dose study completed with data presented at ACR 2024 and ACR 2026. The Phase 2 RELEASE study (NCT07280156) is actively enrolling patients with uncontrolled gout. Topline results are expected in the second half of 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 RELEASE study topline results expected H2 2027
- Potential interim data or updates at medical conferences (e.g., ACR Convergence) in 2027
- Quarterly earnings reports providing pipeline updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Protalix BioTherapeutics, Inc. 8-K PLX ·Originating report